#USA #San Francisco #Alife Health #FutureLife #AI Fertility

FutureLife and Alife Health: Transforming Fertility Care with AI

In a remarkable leap for fertility services, FutureLife Group has announced a strategic partnership with Alife Health to implement an advanced AI platform across its network. This initiative marks FutureLife as the first major European fertility network to adopt such comprehensive technology, aimed at providing enhanced fertility care in 16 different countries.

A Game-Changer for Fertility Treatments

This collaboration introduces the Embryo Predict™ tool, which is CE marked and designed to assist in assessing blastocysts for optimal embryo selection during in vitro fertilization (IVF). By integrating AI into clinical workflows, FutureLife aims to elevate patient experiences and outcomes through improved decision-making processes from the initial stages of treatment to embryo transfer.

“Fertility care should continually evolve to reflect the best available scientific advancements,” stated Francisco Lobbosco, CEO of FutureLife Group. With AI at the heart of these changes, FutureLife is at the forefront of ensuring higher clinical standards and better support systems for patients and their families.

Comprehensive AI Support throughout the Fertility Journey

The AI platform doesn’t just stop at embryo evaluation. It also incorporates several cutting-edge tools intended to streamline and personalize the fertility experience for both patients and healthcare providers. Among these is the Success Predictor™, which provides projections of treatment outcomes even before it begins, and the Egg Retrieval Report, which gives patients insight into their chances of success following egg retrieval. This approach ensures patients are well-informed throughout their IVF journeys.

Amy Barrie, Chief Scientific Officer at FutureLife, highlighted the objective benefits the platform brings: “The integration of this technology provides our clinical teams with a more objective, data-driven foundation for making clinical decisions. It strengthens performance across all our laboratories.”

Standardizing Reports and Enhancing Education

One of the project's key advantages is the potential for standardization. By developing uniform reports between clinics, FutureLife will provide more consistent, data-driven care to patients, minimizing discrepancies that often arise in fertility treatments. Furthermore, resources for both patients and doctors will enhance their understanding and experience.

Melissa Teran, CEO and co-founder of Alife Health, remarked on the significance of this partnership: “When a leading fertility network commits to AI-based treatments, it signals a pivotal shift from experimentation to mainstream practice.”

FutureLife's Operations and Impact

With over 77,000 IVF cycles conducted annually across its 60 clinics in Europe, FutureLife employs more than 2,400 specialists dedicated to guiding patients through their fertility journeys. As a joint venture between CVC and Hartenberg, FutureLife continues to expand its influence by growing organically and through strategic acquisitions. Since its inception in 1991, the group has successfully facilitated the birth of over 185,000 babies, holding a prominent position in the fertility healthcare sector.

The Embryo Predict tool recently received CE certification under the EU's Medical Device Regulation, further solidifying its legitimacy and readiness for widespread use.

Conclusion: The Future of Fertility Care

As FutureLife embarks on this journey with Alife Health, it makes a firm commitment to enhancing its fertility care offerings with the best available technology. This collaboration not only illustrates how AI can revolutionize medical processes but also embodies FutureLife’s vision of a world where everyone has the opportunity to form a family. The path ahead looks promising for future parents seeking assisted reproductive technologies.